A citation-based method for searching scientific literature

Valentina Pirro, Kenneth D Roth, Yanzhu Lin, Jill A Willency, Paul L Milligan, Jonathan M Wilson, Giacomo Ruotolo, Axel Haupt, Christopher B Newgard, Kevin L Duffin. J Clin Endocrinol Metab 2022
Times Cited: 17







List of co-cited articles
79 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Julio Rosenstock, Carol Wysham, Juan P Frías, Shizuka Kaneko, Clare J Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Chrisanthi A Karanikas, Vivian T Thieu. Lancet 2021
134
52

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Juan P Frías, Melanie J Davies, Julio Rosenstock, Federico C Pérez Manghi, Laura Fernández Landó, Brandon K Bergman, Bing Liu, Xuewei Cui, Katelyn Brown. N Engl J Med 2021
207
52

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
356
52

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
218
47

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Stefano Del Prato, Steven E Kahn, Imre Pavo, Govinda J Weerakkody, Zhengyu Yang, John Doupis, Diego Aizenberg, Alan G Wynne, Jeffrey S Riesmeyer, Robert J Heine,[...]. Lancet 2021
69
41

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Mark L Hartman, Arun J Sanyal, Rohit Loomba, Jonathan M Wilson, Amir Nikooienejad, Ross Bray, Chrisanthi A Karanikas, Kevin L Duffin, Deborah A Robins, Axel Haupt. Diabetes Care 2020
97
41

The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Jonathan M Wilson, Amir Nikooienejad, Deborah A Robins, William C Roell, Jeffrey S Riesmeyer, Axel Haupt, Kevin L Duffin, Marja-Riitta Taskinen, Giacomo Ruotolo. Diabetes Obes Metab 2020
33
41

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, Juan P Frias, Laura Fernández Landó, Katelyn Brown, Ross Bray, Ángel Rodríguez. Lancet 2021
86
41

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Melissa K Thomas, Amir Nikooienejad, Ross Bray, Xuewei Cui, Jonathan Wilson, Kevin Duffin, Zvonko Milicevic, Axel Haupt, Deborah A Robins. J Clin Endocrinol Metab 2021
62
41



Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
Naveed Sattar, Darren K McGuire, Imre Pavo, Govinda J Weerakkody, Hiroshi Nishiyama, Russell J Wiese, Sophia Zoungas. Nat Med 2022
33
35


Tirzepatide Once Weekly for the Treatment of Obesity.
Ania M Jastreboff, Louis J Aronne, Nadia N Ahmad, Sean Wharton, Lisa Connery, Breno Alves, Arihiro Kiyosue, Shuyu Zhang, Bing Liu, Mathijs C Bunck,[...]. N Engl J Med 2022
106
35

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
Ricardo J Samms, Michael E Christe, Kyla Al Collins, Valentina Pirro, Brian A Droz, Adrienne K Holland, Jessica L Friedrich, Samantha Wojnicki, Debra L Konkol, Richard Cosgrove,[...]. J Clin Invest 2021
35
35

How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J Samms, Matthew P Coghlan, Kyle W Sloop. Trends Endocrinol Metab 2020
69
35

A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
Kenichi Furihata, Hanaka Mimura, Shweta Urva, Tomonori Oura, Kenji Ohwaki, Takeshi Imaoka. Diabetes Obes Metab 2022
13
38

The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
Jonathan M Wilson, Yanzhu Lin, M Jane Luo, Gary Considine, Amy L Cox, Lenden M Bowsman, Deborah A Robins, Axel Haupt, Kevin L Duffin, Giacomo Ruotolo. Diabetes Obes Metab 2022
17
29


The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Andreas F H Pfeiffer. Diabetes Obes Metab 2021
37
29

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Francis S Willard, Jonathan D Douros, Maria Bn Gabe, Aaron D Showalter, David B Wainscott, Todd M Suter, Megan E Capozzi, Wijnand Jc van der Velden, Cynthia Stutsman, Guemalli R Cardona,[...]. JCI Insight 2020
76
23


GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Juris J Meier. Mol Metab 2021
187
23

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Tim Heise, Andrea Mari, J Hans DeVries, Shweta Urva, Jing Li, Edward John Pratt, Tamer Coskun, Melissa K Thomas, Kieren J Mather, Axel Haupt,[...]. Lancet Diabetes Endocrinol 2022
12
33

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, Stefano Del Prato, David R Matthews, Apostolos Tsapas, Eleni Bekiari. Diabetologia 2022
16
25




Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
Rajaa Nahra, Tao Wang, Kishore M Gadde, Jan Oscarsson, Michael Stumvoll, Lutz Jermutus, Boaz Hirshberg, Philip Ambery. Diabetes Care 2021
50
17

Anti-obesity drug discovery: advances and challenges.
Timo D Müller, Matthias Blüher, Matthias H Tschöp, Richard D DiMarchi. Nat Rev Drug Discov 2022
98
17

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Qian Zhang, Challa Tenagne Delessa, Robert Augustin, Mostafa Bakhti, Gustav Colldén, Daniel J Drucker, Annette Feuchtinger, Cristina Garcia Caceres, Gerald Grandl, Alexandra Harger,[...]. Cell Metab 2021
55
17

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
341
17

Central administration of GLP-1 and GIP decreases feeding in mice.
Cherl NamKoong, Min Sun Kim, Byeong-Tak Jang, Young Hee Lee, Young-Min Cho, Hyung Jin Choi. Biochem Biophys Res Commun 2017
49
17

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Alice E Adriaenssens, Emma K Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y Lam, Ilona Zvetkova, Warren Pan,[...]. Cell Metab 2019
102
17


Targeting BCAA Catabolism to Treat Obesity-Associated Insulin Resistance.
Meiyi Zhou, Jing Shao, Cheng-Yang Wu, Le Shu, Weibing Dong, Yunxia Liu, Mengping Chen, R Max Wynn, Jiqiu Wang, Ji Wang,[...]. Diabetes 2019
120
11

A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance.
Christopher B Newgard, Jie An, James R Bain, Michael J Muehlbauer, Robert D Stevens, Lillian F Lien, Andrea M Haqq, Svati H Shah, Michelle Arlotto, Cris A Slentz,[...]. Cell Metab 2009
11

Amino acid and glucose uptake by rat brown adipose tissue. Effect of cold-exposure and acclimation.
F J López-Soriano, J A Fernández-López, T Mampel, F Villarroya, R Iglesias, M Alemany. Biochem J 1988
43
11

Obesity: global epidemiology and pathogenesis.
Matthias Blüher. Nat Rev Endocrinol 2019
11

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
87
11

Quantitative Analysis of the Whole-Body Metabolic Fate of Branched-Chain Amino Acids.
Michael D Neinast, Cholsoon Jang, Sheng Hui, Danielle S Murashige, Qingwei Chu, Raphael J Morscher, Xiaoxuan Li, Le Zhan, Eileen White, Tracy G Anthony,[...]. Cell Metab 2019
196
11

Adipose tissue branched chain amino acid (BCAA) metabolism modulates circulating BCAA levels.
Mark A Herman, Pengxiang She, Odile D Peroni, Christopher J Lynch, Barbara B Kahn. J Biol Chem 2010
252
11

Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export.
Phillip J White, Amanda L Lapworth, Jie An, Liping Wang, Robert W McGarrah, Robert D Stevens, Olga Ilkayeva, Tabitha George, Michael J Muehlbauer, James R Bain,[...]. Mol Metab 2016
155
11

The BCKDH Kinase and Phosphatase Integrate BCAA and Lipid Metabolism via Regulation of ATP-Citrate Lyase.
Phillip J White, Robert W McGarrah, Paul A Grimsrud, Shih-Chia Tso, Wen-Hsuan Yang, Jonathan M Haldeman, Thomas Grenier-Larouche, Jie An, Amanda L Lapworth, Inna Astapova,[...]. Cell Metab 2018
134
11

BCAA catabolism in brown fat controls energy homeostasis through SLC25A44.
Takeshi Yoneshiro, Qiang Wang, Kazuki Tajima, Mami Matsushita, Hiroko Maki, Kaori Igarashi, Zhipeng Dai, Phillip J White, Robert W McGarrah, Olga R Ilkayeva,[...]. Nature 2019
202
11

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
11

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
393
11

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
167
11

Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.
Mathies M Jepsen, Mikkel B Christensen. Expert Opin Emerg Drugs 2021
14
14

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
975
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.